Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up

被引：0
|
作者：
Marmarelis, M. E. [1 ]
Cantor, D. J. [1 ]
Mathew, D. [1 ]
McWilliams, T. [1 ]
Bauml, J. [2 ]
Hwang, W-T [1 ]
Singh, A. [1 ]
D'Avella, C. [1 ]
Davis, C. [1 ]
Ye, D. [1 ]
Sun, L. [1 ]
Ciunci, C. [1 ]
Aggarwal, C. [1 ]
Cohen, R. B. [1 ]
Minn, A. [1 ]
Wherry, J. [1 ]
Langer, C. J. [1 ]
机构：
[1] Univ Penn, Philadelphia, PA USA
[2] Janssen, Philadelphia, PA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Immunotherapy; JAK; Pembrolizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA06.04
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [41] Beta-interferon, retinoids and tamoxifen in metastatic breast cancer: Long-term follow-up of a phase II study
    Recchia, Francesco
    Sica, Gigliola
    Candeloro, Giampiero
    Necozione, Stefano
    Bisegna, Roberta
    Bratta, Massimo
    Rea, Silvio
    ONCOLOGY REPORTS, 2009, 21 (04) : 1011 - 1016
  • [42] Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1-Positive Metastatic NSCLC
    Hellmann, M. D.
    Cho, B. C.
    Juergens, R.
    Cheng, Y.
    De Castro, G., Jr.
    Erman, M.
    Bauman, J. R.
    Takahashi, T.
    Schwarzenberger, P.
    Zhang, P.
    Pietanza, M. C.
    Yang, J. C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1010 - S1011
  • [43] Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy
    Prelaj, A.
    Sacco, M.
    Miskovic, V.
    Lorenzini, D.
    Trovo, F.
    Zec, A.
    Roisman, L. C.
    Provenzano, L.
    Proto, C.
    Spagnoletti, A.
    Silvestri, C.
    Meya, A.
    Pedrocchi, A.
    Sarris, E.
    Felip, E.
    Reck, M.
    De Braud, F. G. M.
    Lo Russo, G.
    Pearson, A. T.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2024, 35 : S840 - S841
  • [44] Distribution of PD-L1 Tumor Expression by Assay Type in Patients with Metastatic NSCLC (MNSCLC)
    Velcheti, V.
    Cao, X.
    Liu, F.
    Patwardhan, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1779 - S1780
  • [45] A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
    El Osta, Badi
    Carlisle, Jennifer
    Steuer, Conor
    Pakkala, Suchita
    Leal, Ticiana
    Dhodapkar, Madhav
    Liu, Yuan
    Chen, Zhengjia
    Owonikoko, Taofeek
    Ramalingam, Suresh
    CLINICAL LUNG CANCER, 2022, 23 (07) : E400 - E404
  • [46] Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up
    Abreu, D. Rodriguez
    Reck, M.
    Sendur, N.
    Park, K.
    Lee, D. H.
    Cicin, I.
    Yumuk, P. F.
    Orlandi, F. J.
    Leal, T. A.
    Soparattanapaisarn, N.
    Langleben, A.
    Califano, R.
    Medgyasszay, B.
    Hsia, T-C.
    Otterson, G. A.
    Woods, T.
    Jensen, E.
    Samkari, A.
    Boyer, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S30 - S31
  • [47] Benchmarking the efficacy and safety of pembrolizumab plus chemotherapy to pembrolizumab monotherapy: A consecutive analysis of NSCLC patients with high PD-L1 expression
    Takumida, H.
    Horinouchi, H.
    Masuda, K.
    Shinno, Y.
    Okuma, Y.
    Yoshida, T.
    Goto, Y.
    Yamamoto, N.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S855 - S856
  • [48] Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: Long-term follow-up of a 3-week regimen
    Adamo, V
    Magno, C
    Spitaleri, G
    Garipoli, C
    Maisano, C
    Alafaci, E
    Adamo, B
    Rossello, R
    Scandurra, G
    Scimone, A
    ONCOLOGY, 2005, 69 (05) : 391 - 398
  • [49] Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801
    Shinobu Hosokawa
    Eiki Ichihara
    Daijiro Harada
    Shoichi Kuyama
    Koji Inoue
    Kenichi Gemba
    Hirohisa Ichikawa
    Yuka Kato
    Naohiro Oda
    Isao Oze
    Tomoki Tamura
    Toshiyuki Kozuki
    Takahiro Umeno
    Toshio Kubo
    Katsuyuki Hotta
    Akihiro Bessho
    Yoshinobu Maeda
    Katsuyuki Kiura
    International Journal of Clinical Oncology, 2022, 27 : 1139 - 1144
  • [50] Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801
    Hosokawa, Shinobu
    Ichihara, Eiki
    Harada, Daijiro
    Kuyama, Shoichi
    Inoue, Koji
    Gemba, Kenichi
    Ichikawa, Hirohisa
    Kato, Yuka
    Oda, Naohiro
    Oze, Isao
    Tamura, Tomoki
    Kozuki, Toshiyuki
    Umeno, Takahiro
    Kubo, Toshio
    Hotta, Katsuyuki
    Bessho, Akihiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (07) : 1139 - 1144
12345